Alector (ALEC) Stock Price, News & Analysis

Company Overview

Alector, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company uses its expertise in the immune system and neurobiology to investigate treatments designed to improve the brain’s ability to respond to disease and promote the removal or containment of harmful proteins and damaged cells.

Alector’s pipeline has included investigational antibody therapies for conditions such as frontotemporal dementia, Alzheimer’s disease and other neurodegenerative disorders. Its lead programs have included latozinemab (AL001), an antibody being developed for frontotemporal dementia associated with progranulin deficiency, and AL002, an antibody targeting TREM2, a protein involved in microglial function. These candidates remain investigational and are not approved treatments.

Founded in 2013 and headquartered in South San Francisco, California, Alector conducts research and clinical-development activities through collaborations and studies in multiple geographic regions. The company became publicly traded on the Nasdaq under the symbol ALEC in 2019. Alector was co-founded by Arnon Rosenthal, Ph.D., who has served as its chief executive officer, and its development programs have included partnerships with larger pharmaceutical companies.

Key Stats

• Today's Range: $1.93 to $2.03
• 50-Day Range: $1.39 to $2.72
• 52-Week Range: $1.09 to $3.40
• Volume: 508,099 shs
• Average Volume: 930,909 shs
• Market Capitalization: $221.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.63
• Consensus Rating: Hold

Alector Stock Analysis - MarketRank™

Alector scored higher than 40% of companies evaluated by MarketBeat, and ranked 633rd out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Alector has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Alector has a consensus price target of $3.63, representing about 87.8% upside from its current price of $1.93.

Amount of Analyst Coverage

Alector has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alector are expected to grow in the coming year, from ($0.87) to ($0.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Alector is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Alector is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Alector has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.02% of the float of Alector has been sold short.

Short Interest Ratio / Days to Cover

Alector has a short interest ratio ("days to cover") of 4.57.

Change versus previous month

Short interest in Alector has recently increased by 4.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alector does not currently pay a dividend.

Dividend Growth

Alector does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.28

News Sentiment

Alector has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Alector this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for ALEC on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,633.00 in company stock.

Percentage Held by Insiders

8.30% of the stock of Alector is held by insiders.

Percentage Held by Institutions

85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALEC
• CIK: 1653087
• Web: www.alector.com
• Phone: (415) 231-5660
• Fax: N/A
• Employees: 103
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Alector: $3.63
• High Price Target: $6.00
• Low Price Target: $1.50
• Potential Upside/Downside: +81.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$142.93 million
• Net Margins: -850.13%
• Pretax Margin: -847.98%
• Return on Equity: -531.03%
• Return on Assets: -44.00%

Debt

• Debt-to-Equity Ratio: 0.80
• Current Ratio: 5.26
• Quick Ratio: 5.26

Sales & Book Value

• Annual Sales: $21.05 million
• Price / Sales: 10.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 7.13

Miscellaneous

• Outstanding Shares: 111,660,000
• Free Float: 102,389,000
• Market Cap: $222.76 million
• Optionable: Optionable
• Beta: 0.65